Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ARWRBearishAnalyst Ratingnews

Medium materiality6/10

Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses'

Jun 4, 2025, 8:26 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Cramer's skepticism about Arrowhead's profitability indicates potential investor caution. Historical patterns show that negative analyst commentary often precedes stock performance declines.

AI summary

What happened, with direct paths to the underlying reporting

Cramer expressed uncertainty about Arrowhead's financial viability. Arrowhead initiated Phase 1/2a study of ARO-ALK7 for obesity treatment. Cramer highlighted strong performance of Dover Corporation's recent earnings. Arrowhead's shares gained 1.3% to settle at $16.61 on Tuesday.

Cramer expressed uncertainty about Arrowhead's financial viability.
Arrowhead initiated Phase 1/2a study of ARO-ALK7 for obesity treatment.
Cramer highlighted strong performance of Dover Corporation's recent earnings.
Arrowhead's shares gained 1.3% to settle at $16.61 on Tuesday.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses'

Arrowhead's Plozasiran Phase 3 Results Strengthen Redemplo Prospects for FCS

Arrowhead Obesity Drugs Show Significant Fat Loss In Early Human Trials

US FDA approves Arrowhead's genetic disorder drug

Arrowhead Pharmaceuticals Stock Climbs on Plans To Seek FDA Approval for New Drug